Protagonist Therapeutics, Inc. (PTGX)

Market Cap	1.49B
Revenue (ttm)	60.00M
Net Income (ttm)	-78.96M
Shares Out	58.28M
EPS (ttm)	-1.39
PE Ratio	n/a
Forward PE	64.28
Dividend	n/a
Ex-Dividend Date	n/a

Volume	452,330
Open	25.11
Previous Close	25.22
Day's Range	24.79 - 25.63
52-Week Range	13.72 - 33.34
Beta	2.05
Analysts	Strong Buy
Price Target	38.60 (+50.72%)
Earnings Date	May 2, 2024

About PTGX

Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an oral...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Aug 11, 2016
• Employees: 112
• Stock Exchange: NASDAQ
• Ticker Symbol: PTGX

Financial Performance

In 2023, PTGX's revenue was $60.00 million, an increase of 125.73% compared to the previous year's $26.58 million. Losses were -$78.96 million, -38.02% less than in 2022.

Analyst Forecast

According to 6 analysts, the average rating for PTGX stock is "Strong Buy." The 12-month stock price forecast is $38.6, which is an increase of 50.72% from the latest price.

Price Target

$38.6

(50.72% upside)

Analyst Consensus: Strong Buy